M

MacroGenics

D
MGNX
USD
0.29
(6.9544%)
Market Closed
62,050.00
Volume
-1.72
EPS
-
Div Yield
-2.036530
P/E
279,741,208.24
Market Cap
Today
6.9544%
1 Week
22.192%
1 Month
24.061%
6 Months
-72.195%
12 Months
-29.874%
Year To Date
-53.638%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
I
IMGN
(%)
USD
A
ARRY
0.25
(4.223%)
USD
S
SRNE
(%)
USD
N
NKTR
-0.045
(-3.169%)
USD
X
XNCR
0.52
(2.2907%)
USD
B
BLUE
-0.0615
(-14.0764%)
USD
C
CRSP
1.04
(2.0444%)
USD
S
SGMO
0.645
(29.9304%)
USD
E
EDIT
-0.11
(-3.3537%)
USD

Title:
MacroGenics

Sector:
Healthcare
Industry:
Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 CTLA-4), Tebotelimab (PD-1 LAG-3), MGD024 (CD123 CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV CD3).
Do you need help or have a question?
Contact Us